---
title: "Allakos | 10-Q: FY2025 Q1 EPS Meets Estimate at USD -0.29"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239191291.md"
datetime: "2025-05-07T20:04:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239191291.md)
  - [en](https://longbridge.com/en/news/239191291.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239191291.md)
---

# Allakos | 10-Q: FY2025 Q1 EPS Meets Estimate at USD -0.29

EPS: As of FY2025 Q1, the actual value is USD -0.29, meeting the estimate of USD -0.29.

### Segment Revenue

-   Allakos Inc. did not generate any revenue during the three months ended March 31, 2025, as the company is a clinical stage biotechnology firm focused on research and development.

### Operational Metrics

-   **Net Loss**: The company reported a net loss of $26.2 million for the three months ended March 31, 2025, compared to a net loss of $71.1 million for the same period in 2024.
-   **Total Operating Expenses**: Operating expenses decreased to $26.7 million for the three months ended March 31, 2025, from $73.1 million for the same period in 2024, primarily due to reduced research and development expenses and the absence of impairment charges in 2025.
-   **Research and Development Expenses**: These expenses were $13.5 million for the three months ended March 31, 2025, a decrease from $34.8 million in the same period in 2024, due to lower manufacturing and clinical spending.
-   **General and Administrative Expenses**: These expenses increased to $13.2 million for the three months ended March 31, 2025, from $10.9 million in the same period in 2024, primarily due to costs associated with exiting the San Carlos facility.

### Cash Flow

-   **Net Cash Used in Operating Activities**: The company used $28.4 million in net cash for operating activities during the three months ended March 31, 2025, compared to $32.5 million in the same period in 2024.
-   **Net Cash Provided by Investing Activities**: The company generated $33.4 million from investing activities during the three months ended March 31, 2025, primarily from the sale and maturities of investments.

### Unique Metrics

-   **Impairment of Long-Lived Assets**: No impairment charges were recognized during the three months ended March 31, 2025, compared to $27.3 million in charges during the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Allakos Inc. is exploring strategic alternatives to maximize stockholder value, including a merger, sale, or other strategic transaction, following the discontinuation of its AK006 product candidate.
-   **Non-Core Business**: The company has entered into a Merger Agreement with Concentra Biosciences, LLC, which includes a cash tender offer for all outstanding shares of Allakos Inc. common stock at $0.33 per share. The merger is expected to close in May 2025, subject to various conditions.

### Related Stocks

- [ALLK.US](https://longbridge.com/en/quote/ALLK.US.md)